[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355982-105":59,"doc-detail-355982-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","liquid-biopsy-based-metabolomics-in-epithelial-ovarian-cancer-challenges-methodological-advances-and-translational-considerations","Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer - Challenges, Methodological Advances and Translational Considerations","","Epithelial ovarian cancers show pronounced molecular heterogeneity and limited performance of current screening and monitoring strategies, making earlier detection particularly important for genetically predisposed or early-onset patients. This review addresses how liquid biopsy metabolomics captures measurable metabolic signals in peripheral biofluids beyond circulating DNA, RNA, and proteins. It summarizes metabolomics progress across serum, plasma, urine, and ascites, discussing metabolic signatures linked to tumor burden, stage, treatment response, and clinical outcomes while evaluating discrimination between malignant and non-malignant states.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/liquid-biopsy-based-metabolomics-in-epithelial-ovarian-cancer-challenges-methodological-advances-and-translational-considerations/355982/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/liquid-biopsy-based-metabolomics-in-epithelial-ovarian-cancer-challenges-methodological-advances-and-translational-considerations/355982.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is early detection of epithelial ovarian cancer difficult with current strategies?","Question",{"text":113,"@type":114},"Current screening and monitoring approaches have limited sensitivity and specificity, and definitive diagnosis often depends on histopathological evaluation at advanced stages.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What does liquid biopsy-based metabolomics add compared with other liquid biopsy analytes?",{"text":118,"@type":114},"While liquid biopsy often targets circulating DNA, RNA, and proteins, metabolic reprogramming produces informative signals in peripheral biofluids that can complement genomic and histopathological profiling.",{"name":120,"@type":111,"acceptedAnswer":121},"Which types of samples and clinical aspects are covered in the review?",{"text":122,"@type":114},"The review covers analytical platforms applied to serum, plasma, urine, and ascites, and describes metabolic signatures related to tumor burden, disease stage, treatment response, and clinical outcome.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355982,1790238878,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":41,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Review  \nLiquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations  \nMariagrazia D’Agostino 1,†, Luna Laera 1,†, Martina Lanza 2, Doron Tolomeo 1, Monica Montopoli 3, Clelia Tiziana Storlazzi 1, Gennaro Cormio 4,5, Alessandra Castegna 1,* and Stefano Miglietta 1, *  \nAcademic Editor: Edward J. Pavlik  \nReceived: 24 March 2026  \nRevised: 19 June 2026  \nAccepted: 23 June 2026  \nPublished: 25 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Biosciences, Biotechnologies and Environment, University of Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy; [mariagrazia.dagostino@uniba.it](mariagrazia.dagostino@uniba.it) (M.D.); [luna.laera@uniba.it](luna.laera@uniba.it) (L.L.); [doron.tolomeo@uniba.it](doron.tolomeo@uniba.it) (D.T.); [cleliatiziana.storlazzi@uniba.it](cleliatiziana.storlazzi@uniba.it) (C.T.S.)  \n2 Department of Experimental Medicine, University of Salento, Via per Monteroni, 73100 Lecce, Italy; [martina.lanza@unisalento.it](martina.lanza@unisalento.it)  \n3 Department of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy; [monica.montopoli@unipd.it](monica.montopoli@unipd.it)  \n4 Gynecologic Oncology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Tumori“Giovanni Paolo II”, Viale Orazio Flacco 65, 70124 Bari, Italy; [gennaro.cormio@uniba.it](gennaro.cormio@uniba.it)  \n5 Department of Interdisciplinary Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11,  \n70124 Bari, Italy  \n* Correspondence: [alessandra.castegna@uniba.it](alessandra.castegna@uniba.it) (A.C.); [stefano.miglietta@uniba.it](stefano.miglietta@uniba.it) (S.M.)† These authors contributed equally to this work.  \nAbstract  \nEpithelial ovarian cancers (EOCs) histotypes are characterized by marked molecular heterogeneity and limited effectiveness of current screening and monitoring strategies. Earlier identification of tumor-associated alterations may support timely intervention, especially in genetically predisposed or early-onset patient populations. While liquid biopsy approaches have primarily focused on circulating DNA, RNA, and proteins, increasing evidence indicates that cancer-associated metabolic reprogramming generates measurable informative signals in peripheral biofluids. This review summarizes recent progress in liquid biopsyderived metabolomics in EOCs, covering analytical platforms applied to serum, plasma, urine, and ascites. Recurrent metabolic signatures linked to tumor burden, disease stage, treatment response, and clinical outcome are described, and their significance in discriminating malignant and non-malignant conditions is critically discussed. Collectively, these findings suggest that metabolomics may provide complementary functional information alongside genomic and histopathological profiling. Although its clinical implementation still requires further validation and methodological standardization, ongoing advancesin analytical technologies and the integration of high-dimensional metabolic data into machine learning-based frameworks may progressively support the identification of early tumor-associated alterations and contribute to more accurate disease stratification and biologically informed clinical management.  \nKeywords: ovarian cancer; liquid biopsy; metabolomics; cancer reprogramming; biomarkers; precision medicine  \n1. Introduction  \nOvarian cancer (OC) represents one of the most lethal malignancies affecting the female reproductive system, largely due to its asymptomatic onset and the lack of effective strategies for early detection. Current screening approaches remain inadequate: widely used serum markers, such as the ovarian carcinoma antigen CA125, lack sufficient sensitivity and specificity for ea","cbCaiukqipZP82DS","https://ap.wps.com/l/cbCaiukqipZP82DS","pdf",2493832,"English","# Introduction\n## Liquid biopsy and metabolomics rationale\n# Objectives and scope","[{\"question\":\"Why is early detection of epithelial ovarian cancer difficult with current strategies?\",\"answer\":\"Current screening and monitoring approaches have limited sensitivity and specificity, and definitive diagnosis often depends on histopathological evaluation at advanced stages.\"},{\"question\":\"What does liquid biopsy-based metabolomics add compared with other liquid biopsy analytes?\",\"answer\":\"While liquid biopsy often targets circulating DNA, RNA, and proteins, metabolic reprogramming produces informative signals in peripheral biofluids that can complement genomic and histopathological profiling.\"},{\"question\":\"Which types of samples and clinical aspects are covered in the review?\",\"answer\":\"The review covers analytical platforms applied to serum, plasma, urine, and ascites, and describes metabolic signatures related to tumor burden, disease stage, treatment response, and clinical outcome.\"}]","Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer - Challenges, Methodological Advances and Translational Considerations | PDF",1790122057,76,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61e2309aea8a3c6038ad8982d15946a2.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01131da2a09b0b1b7af4becefb8fd0f3.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3253a15a13c11ccfb728678d59fd77fe.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/985105710b29d52447b000c31b5ffe2b.webp",980,1385]